Genetic Technologies Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNTLF research report →
About the company
Genetic Technologies Limited, trading as GNTLF, is an Australian molecular diagnostics enterprise dedicated to creating and delivering advanced predictive assessment instruments. These tools are designed to assist medical professionals in Australia and the United States with managing women's health. The company's primary offering is BREVAGenplus, a meticulously validated risk evaluation test specifically for non-inherited breast cancer.
- CEO
- Kevin Camilleri
- IPO
- 2000
- Employees
- 55
- HQ
- Fitzroy, VIC, AU
Price Chart
- Market Cap
- $1.34B
- P/E
- -0.43
- P/S
- 0.74
- P/B
- 2.95
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 50.94%
- Op Margin
- -159.30%
- Net Margin
- -156.78%
- ROE
- -184.98%
- ROIC
- -429.43%
- Revenue
- $9.67M · -6.52%
- Net Income
- $-12,017,219 · -2.27%
- EPS
- $-0.09 · 24.25%
- Op Income
- $-12,210,212
- FCF YoY
- 0.29%
- 52W High
- $1.00
- 52W Low
- $1.00
- 50D MA
- $1.00
- 200D MA
- $1.00
- Beta
- 0.15
- Avg Volume
- 71.6
Get TickerSpark's AI analysis on GNTLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GNTLF coverage
Recent articles, reports, and earnings notes.
No research on GNTLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNTLF report →Similar companies
Peers in the same neighborhood.